Synthetic Drugs: Myths, Facts, And Strategies

3y ago
34 Views
2 Downloads
8.51 MB
102 Pages
Last View : 1m ago
Last Download : 3m ago
Upload by : Anton Mixon
Transcription

Substance Abuse Treatment and Mental HealthServices Integration Taskforce (SATMHSIT) presentsSynthetic Drugs: Myths, Facts, and StrategiesA SymposiumFebruary 19, 2013Planning CommitteeCriminal Justice Coordinating CouncilCourt Services and Offender Supervision AgencyAddiction Prevention and Recovery AdministrationDistrict of Columbia Department of HealthPretrial Services AgencyUnited States Parole CommissionMetropolitan Police Department

Table of ContentsLetter from the Executive Director of the Criminal Justice Coordinating Council . 3Agenda . 4Summary . 8Presentations .12Video Vignettes.13Synthetic Drugs 101: Trafficking and Abuse Trends .16Challenge and National Response to Synthetic Drugs .90Local Public Health and Treatment Overview . 103Local Impact Panel. 118Handout . 144Case Study . 146Legislation . 150Feedback . 171Biographies . 173About the Criminal Justice Coordinating Council. 190Acknowledgements . 192

003

004Substance Abuse Treatment and Mental HealthServices Integration Taskforce (SATMHSIT) presentsSynthetic Drugs: Myths, Facts, and StrategiesA SymposiumFebruary 19, 2013AGENDA

005The Substance Abuse Treatment and Mental Health Services Integration Taskforce presentsSYNTHETIC DRUGS: MYTHS, FACTS, AND STRATEGIESA SymposiumSYMPOSIUM AGENDA9:00WELCOMEMannone A. Butler, Executive Director, Criminal Justice Coordinating CouncilPaul A. Quander Jr., Deputy Mayor for Public Safety and Justice9:10VIDEO VIGNETTESJordana Randall, Program Coordinator, United States Parole CommissionKaren Johnson, Supervisory Community Supervision Officer, Court Services and Offender Supervision Agency9:20SYNTHETIC DRUGS 101A presentation of what synthetic drugs are and information that has been gathered to date on theimpact of these drugs on the body.Alan Santos, Associate Deputy Assistant Administrator, Office of Diversion Control, Drug EnforcementAdministration

00610:00STATE AND FEDERAL RESPONSES TO SYNTHETIC DRUGSAn overview of federal and state legislative policy, best practices, and enforcement efforts,including responses to supply control, demand reduction, national health trends, treatment, andguidance.Moderator: Cedric Hendricks, Associate Director of the Office of Legislative, Intergovernmental, and PublicAffairs, Court Services and Offender Supervision AgencyJane Erisman, Senior Attorney, Office of the Chief Counsel, Drug Enforcement AdministrationRichard Baum, Chief of International Policy, Office of Supply Reduction, Office of National Drug ControlPolicyDr. Anthony Campbell, Clinical Specialty Consultant, Substance Abuse and Mental Health ServicesAdministration11:10BREAK11:20LOCAL PUBLIC HEALTH & TREATMENT OVERVIEWAn overview of the District’s current and emerging responses to synthetic drugs from a publichealth perspective.Moderator: Keela Seales, Chief of Policy and Planning, Addiction Prevention and Recovery AdministrationTodd Menhinick, Chief of Quality Assurance, Addiction Prevention and Recovery AdministrationJavon Oliver, Director of Treatment, Addiction Prevention and Recovery AdministrationDr. Nura Green, Strategic Prevention Framework State Incentive Grant Coordinator, Wards 7 & 8 DCPrevention Center, Addiction Prevention and Recovery Administration12:00LOCAL IMPACT OF SYNTHETIC DRUGS (LUNCH PANEL)An overview of the multi-systemic impact of synthetic drugs in the District of Columbia, which willgenerate a community dialogue about it.Moderator: Terrence Walton, Director of Treatment Programs, Pretrial Services AgencyMelvin Scott, Commander, Metropolitan Police DepartmentAdrienne Poteat, Deputy Director, Court Services and Offender Supervision AgencyBonita Bantom, Clinical Specialist, District of Columbia Public SchoolsFrederick Weisberg, Judge, District of Columbia Superior CourtCharles Dark, Director, DC Prevention Center Wards 5 & 6, Sasha Bruce Youthwork2

0071:00BREAKOUT SESSION: CASE STUDY REVIEW WORKGROUPSAn interactive session to conduct a subject matter specific review of a case study, identify issues,and provide recommendations.Moderator: Charisma Howell, Deputy Executive Director, Criminal Justice Coordinating CouncilKaren Johnson, Supervisory Community Supervision Officer, Court Services and Offender Supervision AgencySharon Banks, Program Analyst, Pretrial Services AgencyKeela Seales, Chief of Policy and Planning, Addiction Prevention and Recovery AdministrationMichen Tah, Policy Analyst, Criminal Justice Coordinating Council2:30BREAK2:40DISTRICT’S RESPONSES TO SYNTHETIC DRUGSA forum for the District’s public safety and health leaders to discuss current and future strategies.Moderator: Paul A. Quander Jr., Deputy Mayor for Public Safety and JusticeCliff Keenan, Director, Pretrial Services AgencyNancy Ware, Director, Court Services and Offender Supervision AgencyMelvin Scott, Commander, Metropolitan Police DepartmentNicholas Majett, Director, Department of Consumer and Regulatory AffairsSaul Levin, Director, Department of HealthDr. Jason Kolowski, Director of the Forensic Science Laboratories, Department of Forensic SciencesJohn Dominguez, Lead Taskforce Attorney for the Organized Crime Drug Enforcement Taskforce, UnitedStates Attorney’s OfficeTerri Odom, Director of the Family Court Social Services Division, District of Columbia Superior Court4:00CLOSING REMARKSMannone A. Butler, Executive Director, Criminal Justice Coordinating Council3

008Substance Abuse Treatment and Mental HealthServices Integration Taskforce (SATMHSIT) presentsSynthetic Drugs: Myths, Facts, and StrategiesA SymposiumFebruary 19, 2013SUMMARY

009Synthetic Drugs: Myths, Facts, and Strategies was a symposium presented by the CriminalJustice Coordinating Council’s Substance Abuse Treatment and Mental Health Services IntegrationTaskforce to bring law enforcement, criminal justice, health, human services, and business leaderstogether to raise awareness about the proliferation of synthetic drug use in the District of Columbia.Beyond raising awareness and given the public health and public safety concerns related to theemergence of synthetic drug use in the community, the purpose of the symposium was also togenerate a dialogue geared towards engineering a comprehensive and coordinated approach to addressthe issue.During the Synthetic Drugs 101 presentation, symposium attendees learned about whatsynthetic drugs are and information that has been gathered to date on the effect these drugs have onthe body. The State and Federal Responses to Synthetic Drugs panelists provided an overview offederal and state legislative policy, best practices, and enforcement efforts, including responses tosupply control, demand reduction, national health trends, treatment, and guidance. The Local PublicHealth and Treatment Overview provided information about current and emerging responses tosynthetic drugs from a public health perspective. The panelists on the Local Impact of SyntheticDrugs panel explored the multi-systemic impact of synthetic drugs in the District of Columbia.During the breakout session, symposium attendees collaborated with each other to identify issuesraised in a case study and provide recommendations for addressing those issues. The District’sResponses to Synthetic Drugs panel served as a forum for the District’s public safety and healthleaders to discuss current and future strategies for quelling the proliferation of synthetic drug use inthe community.Synthetic drugs, which include synthetic cannabinoids and synthetic cathinones, areperceived as being “legal” alternatives to drugs like marijuana, cocaine, methamphetamine, andMDMA (Ecstasy). Manufacturers of synthetic drugs mine scientific literature to create thesesubstances, which are produced to mimic the effects of controlled substances. Synthetic cannabinoidsare a large family of chemically unrelated structures that are designed to be functionally similar toTHC, the principal psychoactive constituent of marijuana. Colloquially referred to as K2 or Spice,synthetic cannabinoids are sold in retail stores and on the internet as “herbal incense” or “potpourri.”People who smoke synthetic cannabinoids may experience adverse health effects affecting thepsychological, neurological, cardiovascular, metabolic, gastrointestinal, and autonomic systems.Synthetic cathinones are structurally and pharmacologically similar to amphetamine, Ecstasy, andother related substances, which stimulate the central nervous system. Synthetic cathinones are sold inretail stores and on the internet as “bath salts,” “plant food,” and “jewelry cleaner.” People who haveconsumed synthetic cathinones may experience adverse health effects affecting the cardiovascular,

010psychological, neurological, musculoskeletal, gastrointestinal, pulmonary, and otolaryngologicalsystems.The availability of synthetic drugs for purchase through internet sales, head shops, andsmoke shops, as well as their promotion on discussion boards, has fostered the increasing popularityof synthetic drugs among recreational drug users. Synthetic drugs, which are also referred to as“designer drugs,” are usually marketed to teens and young adults and are readily available in retailenvironments and via the internet. These drugs contain unknown ingredients, are not tested forhuman consumption, and interact in the body with other drugs and alcohol in a way that has notbeen studied. There is no consistency in the manufacturing process or regulation of the locations inwhich they are produced, so their potency and composition can vary from batch to batch andmanufacturer to manufacturer. Public safety concerns raised by synthetic drug use include fatalitiescaused by users driving under the influence, homicides, suicides, overdoses, and abuse of these drugsin order to evade drug screens.The DEA National Forensic Laboratory Information System (NFLIS) systematically collectsresults from drug chemistry analyses conducted by state and local forensic laboratories across thecountry. The NFLIS reported exponential increases in law enforcement seizures of syntheticcannabinoids and synthetic cathinones since 2009. For synthetic cannabinoids, the figures jumpedfrom 23 in 2009 to 3,285 then 22,989 and 32,504 in the succeeding years, respectively. For syntheticcathinones, the figures rose from 26 in 2009 to 729 then 6,772 and 11,275 in the succeeding years,respectively. These numbers reflect a proliferation in the supply of synthetic drugs throughout thecountry. In 2009, law enforcement seized 2 varieties of synthetic cannabinoids and 4 varieties ofsynthetic cathinones. As of January 2013, law enforcement has seized 51 varieties of syntheticcannabinoids and 31 varieties of synthetic cathinones, an increase that reflects the cunning ofmanufacturers in altering the chemical composition of synthetic drugs in order to sidestep lawsbanning the substances.At the federal level, efforts underway to take on the issue of synthetic drugs includepermanent scheduling, temporary scheduling, new legislation, the Controlled Substance Analogue Actof 1986, and law enforcement efforts like Operation Logjam.Locally, there are programs underway geared toward addressing substance abuse by youth orby individuals involved in the criminal justice system. DCPS announced a partnership with DMH inan evidence-based, data-driven effort to address youth substance abuse in a natural setting. Providershave been trained in 13 high schools, and training will begin in middle and elementary schools nextyear. Additionally, Sasha Bruce Youthwork highlighted its multi-tiered work with youth, whichincludes organizing protests directed towards places that sell synthetic drugs.Panelists throughout the day acknowledged the challenges facing the community, substanceabuse treatment practitioners, and law enforcement in efforts to get ahead of this burgeoning issue.For instance, in light of the inability to test for synthetic drug use, CSOSA is not able to adequatelyplace client who may be addicted to those substances. Likewise, it is difficult for law enforcement tomake arrests related to synthetic drug possession and distribution because there are no field tests to2

011determine what the substance is and the turnaround time for offsite laboratories with testing capacityis lengthy. In schools, these substances hinder the ability to learn.The general sentiment was that a concerted and multi-faceted effort is required. Fourproposed solutions arose out of the discussions at the symposium: (1) develop legislation to ensurethat synthetic drugs are illegal, (2) create disincentives for retailers who sell substances that areknown to be synthetic drugs, (3) develop and improve methods to detect synthetic drugs, and (4)increase public awareness about synthetic drugs and its impact on the individuals who consume them.The Council of the District of Columbia (“DC Council”) recently passed the Omnibus CriminalCode Amendments Act (“Bill 19-645”), which, among other things, made many synthetic drugs illegalin the District of Columbia. Bill 19-645 is currently undergoing congressional review. In themeantime, provisions of Bill 19-645, including those regarding synthetic drugs, were adopted on anemergency basis through the Omnibus Criminal Code Amendments Emergency Amendment Act of2012 (“DC Act 19-599”) and went into effect on January 14, 2013.Another suggestion that arose from the symposium centered on the business community.Synthetic drugs are often sold in gas station convenience stores and “head shops” as potpourri,incense, or plant fertilizer. They are sold in brightly-colored packages, with names such as ScoobySnax, and are geared to a younger demographic. Anecdotal evidence was presented at the symposiumindicating that shop owners are aware of the demographic likely to purchase these products as well ashow they are used once purchased. Therefore, it was suggested that an agency, such as theDepartment of Consumer and Regulatory Affairs, impose fines or other disincentives on retailers todiscourage the sale of items known to be consumed as synthetic drugs.A third challenge facing those trying to stem the rising prevalence of synthetic drug use in theDistrict of Columbia is the difficulty in detecting the substances. This challenge is not onlyproblematic on the treatment front, but also with respect to law enforcement and general regulatoryefforts. Although tests exist to detect synthetic drugs, they are costly and are not widely available. Aswith legislation, changes to the composition of synthetic drugs are currently outpacing advances indetection. The desire to develop additional testing is twofold. First, less expensive testing options areneeded. Second, testing options, including field tests, need to be made more widely available toprofessionals who encounter individuals who may have used synthetic drugs.Finally, symposium attendees and panelists concluded that increasing public awareness aboutthe issue of synthetic drugs is imperative. To this end, it was suggested that a group be convened todevelop an informational campaign (television, radio, print, and/or social media) about syntheticdrugs in order to empower youth and the community at large to tackle the issue of synthetic drug use.This symposium and the proposed solutions that arose from our discussions are merely thefirst steps to tackling the emergence of synthetic drug use in the District of Columbia. As many of younoted in your feedback about the symposium, we must continue the conversation about syntheticdrugs, we must follow up on the action items, and we must make every effort to get ahead of thisissue quickly.3

012Substance Abuse Treatment and Mental HealthServices Integration Taskforce (SATMHSIT) presentsSynthetic Drugs: Myths, Facts, and StrategiesA SymposiumFebruary 19, 2013PRESENTATIONS

013Synthetic Drugs:Myths, Facts, and StrategiesVideo Vignettes

014Bath Salts Craze Caught on TapePosted ByABC NewsDuration2:07DateJune 4, 2007Linkhttp://youtu.be/bXo-0iFj8Ys

015CBS News – Synthetic MarijuanaPosted ByjwkindestinDuration2:51DateAugust 7, 2010 (aired May 2010)Linkhttp://youtu.be/CtmrMuehC6w

016

017

018

019

020

021

022

023

024

025

026

027

028

029

030

031

032

033

034

035

036

037

038

039

040

041

042

043

044

045

046

047

048

049

050

051

052

053

054

055

056

057

058

059

060

061

062

063

064

065

066

067

068

069

070

071

072

073

074

075

076

077

078

079

080

081

082

083

084

085

086

087

088

089

090Challenge and National Responseto Synthetics DrugsThe Synthetic Drug SymposiumCriminal Justice Coordinating CouncilFebruary 19, 2013Richard BaumChief, International Policy BranchRbaum@ondcp.eop.gov

A Rapidly Emerging Threat091 Addressing the threat posed by these new Synthetics is a majorpriority of the Obama Administration. We are working with our Federal partners to employ Federalauthorities to take action and gather as quickly as we can. State and local agencies also play a vital in responding to this threat –in fact it is essential that they use their State health, safety, andagricultural authorities to get these products off the shelves. Synthetic cannabinoids in herbal incense products were first detectedin the United States in November 2008, by DEA’s forensic laboratory. According to the American Association of Poison Control Centers,2,906 calls relating to human exposure to synthetic marijuana werereceived in 2010. Twice that number (6,959) were received in 2011, and 639 had beenreceived as of January 2012. The number of calls related to bath salt exposure received by poisoncontrol centers across the country increased by more than 20 times in2011 alone, up from 304 in 2010 to 6,138.

092THC-like Substances “Spice” / K2 An herbal mixture called “Spice”and K2 is sold in Europeancountries and in the U.S. via theInternet, head shops, tobaccoshops and other retail venues. “Spice” and K2 are found tocontain substances withmarijuana-like psychoactiveeffects (e.g., HU-210, HU-211,JWH-018, JWH-073 and CP47,947 & homologues)is abused bysmoking.and it

Ivory Wave / Vanilla Sky Sold on Internet and in headshops as “bath salts” Chemical(s): MDPV & methylone

Synthetic cathinones are structurally and pharmacologically similar to amphetamine, Ecstasy, and other related substances, which stimulate the central nervous system. . develop and improve methods to detect synthetic drugs, and (4) . Bill 19-645 is currently undergoing congressional review. In the meantime, provisions of Bill 19-645 .

Related Documents:

The following Fact Fluency Card labels are included in this pack: 1. Plus One Facts 2. Plus Two Facts 3. Plus Three Facts 4. Minus One Facts 5. Minus Two Facts 6. Minus Three Facts 7. Facts of Five 8. Doubles Facts (Addition) 9. Doubles Facts (Subtraction) 10. Near Doubles Facts (e.g. 6 7 6 6 1 12 1 13) 11. Facts of Ten: Addition 12.

doubles-plus-one facts, doubles-plus-two facts, plus-ten facts, plus-nine facts, and then any remaining facts. For multiplication, the suggested sequence is the times-zero principle, times-one principle, times-two and two-times facts, times-five and five-times facts, times-nine and nine-times facts, perfect squares, and then any remaining facts .

Drugs Affecting Autonomic Nervous System, 2. Drugs Affecting Central Nervous System, 3. Drugs Affecting Cardiovascular System, 4. Drugs Affecting Haemostasis and Thrombosis, 5. Drugs Affecting Renal Function, 6. Drugs Affecting Endocrine System, 7. Drugs Affecting Respiratory System, 8. Drugs Affecting Gastr

Math Bee Practice . 1st Round Mixed Multiplication and Division Facts 2 seconds. Multiplication Facts 6 x 6 _ Multiplication Facts 6 x 6 36. Multiplication Facts 32 8 _ Multiplication Facts 32 8 4. Multiplication Facts 7 x 6 _ Multiplication Facts 7 x 6 42. Multiplication Facts 56 7 _

These include drugs affecting the autonomic nervous system; anesthetics and analgesics; drugs to treat the heart and diseases of the cardiovascular system; drugs affecting the pulmonary system; antibiotics; drugs used to treat psychiatric disorders; drugs of abuse and drugs use to treat addiction; drugs that affect the immune

b. Drugs acting on Central Nervous system: Analgesics, Nonsteroidal anti inflammatory drugs, Sedatives and Hypnotic, Anti convulsants and Antipsychotic drugs. Drugs used in parkinsonism. c. Drugs acting on Autonomic Nervous system: Drugs which influence the working of autonomic nervous system, Adrencrgic drugs

NDC labeler code 47335 (Sun Pharmaceutical Industries, Inc.) only. drugs cdl p1a 3 Part 2 – Drugs: Contract Drugs Lists Part 1 – Prescription Drugs (A through D) Page u

Adventure tourism: According to travel-industry-dictionary adventure tourism is “recreational travel undertaken to remote or exotic destinations for the purpose of explora-tion or engaging in a variety of rugged activities”. Programs and activities with an implica-tion of challenge, expeditions full of surprises, involving daring journeys and the unexpect- ed. Climbing, caving, jeep .